Grande E - Search Results

1

GEP-NETs update: Biotherapy for neuroendocrine tumours.

Alonso-Gordoa T, Capdevila J, Grande E. Alonso-Gordoa T, et al. Among authors: grande e. Eur J Endocrinol. 2015 Jan;172(1):R31-46. doi: 10.1530/EJE-14-0354. Eur J Endocrinol. 2015. PMID: 25430657 Review.

2

Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs).

Grande E, Díez JJ, Pachón V, Carrato A. Grande E, et al. Clin Transl Oncol. 2010 Jul;12(7):481-92. doi: 10.1007/s12094-010-0541-5. Clin Transl Oncol. 2010. PMID: 20615825 Review.

3

Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor.

Grande E, José Díez J, Pachón V, Angeles Vaz M, Longo F, Guillén C, García de Paredes ML, Carrato A. Grande E, et al. Anticancer Drugs. 2011 Jun;22(5):477-9. doi: 10.1097/CAD.0b013e328344484b. Anticancer Drugs. 2011. PMID: 21346550

4

Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?

Grande E, Capdevila J, Barriuso J, Antón-Aparicio L, Castellano D. Grande E, et al. Cancer Metastasis Rev. 2012 Jun;31(1-2):47-53. doi: 10.1007/s10555-011-9328-6. Cancer Metastasis Rev. 2012. PMID: 22105614 Review.

5

Sorafenib in metastatic thyroid cancer.

Capdevila J, Iglesias L, Halperin I, Segura A, Martínez-Trufero J, Vaz MÁ, Corral J, Obiols G, Grande E, Grau JJ, Tabernero J. Capdevila J, et al. Among authors: grande e. Endocr Relat Cancer. 2012 Apr 10;19(2):209-16. doi: 10.1530/ERC-11-0351. Print 2012 Apr. Endocr Relat Cancer. 2012. PMID: 22285864

6

Thyroid cancer: molecular aspects and new therapeutic strategies.

Grande E, Díez JJ, Zafon C, Capdevila J. Grande E, et al. J Thyroid Res. 2012;2012:847108. doi: 10.1155/2012/847108. Epub 2012 Jul 12. J Thyroid Res. 2012. PMID: 22848860 Free PMC article.

7

The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.

De Dosso S, Grande E, Barriuso J, Castellano D, Tabernero J, Capdevila J. De Dosso S, et al. Among authors: grande e. Cancer Metastasis Rev. 2013 Dec;32(3-4):465-77. doi: 10.1007/s10555-013-9421-0. Cancer Metastasis Rev. 2013. PMID: 23589060 Review.

8

Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.

Grande E, Kreissl MC, Filetti S, Newbold K, Reinisch W, Robert C, Schlumberger M, Tolstrup LK, Zamorano JL, Capdevila J. Grande E, et al. Adv Ther. 2013 Nov;30(11):945-66. doi: 10.1007/s12325-013-0069-5. Epub 2013 Nov 19. Adv Ther. 2013. PMID: 24249433 Free PMC article. Review.

9

A significant response to sunitinib in a patient with anaplastic thyroid carcinoma.

Grande E, Capdevila J, Díez JJ, Longo F, Carrato A. Grande E, et al. J Res Med Sci. 2013 Jul;18(7):623-5. J Res Med Sci. 2013. PMID: 24516498 Free PMC article.

10

What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?

Capdevila J, Carrato A, Tabernero J, Grande E. Capdevila J, et al. Among authors: grande e. Crit Rev Oncol Hematol. 2014 Nov;92(2):83-106. doi: 10.1016/j.critrevonc.2014.05.004. Epub 2014 May 14. Crit Rev Oncol Hematol. 2014. PMID: 24924525 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

352 results

Search Page

Filters